Dr Sue-Ann Ng, Associate Consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, speaks to Roshini Claire Anthony on the multisystemic autoimmune disease that is systemic sclerosis (SSc) and the importance of early identification of the condition.
Roshini Claire Anthony speaks with Dr Annie Law, a consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, on how primary care physicians can help in the management of systemic lupus erythematosus (SLE).
A 36-year-old banker with good past health presented to our rheumatology clinic with a 6-month history of bilateral wrist pain. He initially sought medical attention in the private sector for a 2-month history of bilateral symmetrical wrist pain and swelling.
Dr. Priscilla Wong, Dr. Lydia Tam, Prof. LS Tam, 20171110000000
This case report highlights that psoriatic arthritis is a heterogenous disease affecting multiple disease domains, and effective treatment requires thorough assessment of each of these different domains.
Spinal fractures are often the result of underlying osteoporosis. Radha Chitale spoke with Dr. Hee Hwan Tak, medical director and senior consultant at the Pinnacle Spine & Scoliosis Centre at Mount Elizabeth Medical Centre, about managing osteoporotic spinal fractures in primary care.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Rheumatology digital copy today!
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.